pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Pathos AI Inc

updated 5mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 2: 1
1Phase 2
Phase 2
pocenbrodib hydrochloride
Metastatic Castration-Resistant Prostate Cancer (mCRPC)

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Pathos AI Inc jobs →

News

  • Pathos raises $237M at $3B valuation, signs Bristol Myers neuro partnership
    AI-driven biotech Pathos AI has corralled a $237 million Series E at a $3 billion valuation, the New York-based company said on Wednesday. The large fundraise comes in below the $300 million that t…
    endpoints · 27d ago
  • BMS leads Pathos AI's $237M series E alongside Alzheimer's link-up
    Pathos AI has closed a $237 million series E round led by pharma giant Bristol Myers Squibb on the same day that the two companies signed a cutting-edge Alzheimer's disease-focused collaboration.
    fiercebiotech · 1mo ago
  • Pathos inks BMS, Tempus collabs to apply agentic AI in Alzheimer's clinical development
    Pathos AI has signed two new collaboration deals aimed at developing drugs for neurological conditions such as Alzheimer's disease, one with pharma giant Bristol Myers Squibb and another with Tempu…
    fiercebiotech · 1mo ago
  • J&J pharma leader to retire; Krystal slumps on gene therapy miss
    Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.
    biopharma_dive · 3mo ago
  • Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab
    Pathos AI could pay more than $2 billion to a Jiangsu Alphamab Biopharmaceuticals subsidiary for a late-stage bispecific antibody-drug conjugate for breast cancer, while the financial details of th…
    biospace · 3mo ago
  • Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact
    Pathos AI has agreed to pay $125 million for a bispecific antibody-drug conjugate from China’s Alphamab Oncology, while adding a Big Pharma partner in the form of AstraZeneca.
    fiercebiotech · 3mo ago
  • Pathos does deals with AstraZeneca, China's Alphamab, seeks up to $300M Series E
    Pathos AI is firing on all cylinders. The technology and drug development company told Endpoints News that it signed a major antibody-drug conjugate deal with a Chinese biotech and teamed up with i…
    endpoints · 3mo ago
identifiers
source
globaldata
top tags
Oncology1
mentioned in
7news items
entity-linker matched
Data sources
openFDA
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?